|
|
|
| Clinical effect of Salmeterol Fluticasone and low-dose Erythromycin in the treatment of bronchiectasis |
| DING Shuang |
| Department of Respiratory Medicine, Iron and Coal General Hospital of Liaoning Health Industry Group, Liaoning Province, Tieling 112700, China |
|
|
|
|
Abstract Objective To explore the clinical effect of Salmeterol Fluticasone + low-dose Erythromycin in the treatment of bronchiectasis.Methods A total of 120 patients with bronchiectasis admitted to our hospital from June 21, 2018 to June 21, 2019 were selected as the research objects, and they were randomly divided into two groups according to the single and double numbers, 60 cases in each group, and the control group was treated with Erythromycin, the observation group was treated with Salmeterol Fluticasone + low-dose Erythromycin, and then the forced vital capacity (FVC),peak expiratory flow rate (PEF), forced expiratory volume in one second (FEV1), cough sputum score, cough score,shortness of breath score, total incidence of adverse reactions, time of disappearance of sputum, time of disappearance of lung rales, and time of body temperature returning to normal were compared.Results The PEF ([4.76±0.37] L/s), FVC([2.76±0.41] L), FEV1([1.92±0.46] L) of the observation group after treatment were higher than those of the control group PEF ([3.49±0.42] L/s), FVC ([2.11±0.19] L), FEV1 ([1.45±0.11] L), the differences were statistically significant (P＜0.05).The observation group′s shortness of breath score ([0.37±0.08] points), expectoration score ([0.44±0.19] points), cough score ([0.62±0.19] points), the total incidence of adverse reactions (3.33%) were lower than those of the control group for shortness of breath score ([1.54±0.27] points), expectoration score ([1.65±0.28] points), cough score ([1.43±0.28]points), total incidence of adverse reactions (26.67%), the differences were statistically significant (P＜0.05), the time of disappearance of lung rales in the observation group ([3.16±0.52] d), the time of disappearance of sputum ([1.26±0.68]d), the time of body temperature returning to normal ([2.27±1.54] d) were all shorter than those of the control which the disappearance time of lung rales [(4.87±1.55) d], the disappearance time of sputum ([3.68±1.53] d) and the time of body temperature returning to normal ([4.61±1.27] d), the differences were statistically significant (P＜0.05).Conclusion Salmeterol Fluticasone plus low-dose Erythromycin in patients with bronchiectasis has a significant effect, which can reduce the incidence of adverse reactions.
|
|
|
|
|
|
| [1] |
汤希邦.沙美特罗氟替卡松联合小剂量红霉素口服治疗支气管扩张症的临床疗效观察[J].航空航天医学杂志，2015，35（6）：743-744.
|
| [2] |
帖永新.观察长期吸入沙美特罗氟替卡松联合小剂量红霉素对支气管扩张症的临床疗效[J].中国伤残医学，2015，32（16）：104-105.
|
| [3] |
苏湘珍.观察长期吸入沙美特罗氟替卡松联合小剂量红霉素对支气管扩张症的临床疗效[J].中国实用医药，2015，33（20）：169-170.
|
| [4] |
贺素锦.观察长期吸入沙美特罗/氟替卡松联合小剂量红霉素对支气管扩张症的临床疗效[J].中国实用医药，2015，10（36）：144-145.
|
| [5] |
田玉恒.长期吸入沙美特罗/氟替卡松联合小剂量红霉素对支气管扩张症的临床疗效[J].北方药学，2018，15（2）：124-125.
|
| [6] |
沙正凯，张祥杰，翟成凯，等.长期吸入沙美特罗/氟替卡松联合小剂量红霉素对支气管扩张症的疗效观察[J].中国现代药物应用，2016，10（14）：176-177.
|
| [7] |
陈景行.观察长期吸入沙美特罗氟替卡松联合小剂量红霉素对支气管扩张症的临床疗效[J].临床研究，2015，45（11）：78.
|
| [8] |
孟兆平.小剂量红霉素长疗程口服治疗支气管扩张症稳定期50 例[J].中国药业，2015，24（23）：232-234.
|
| [9] |
周继朴，李峻，郭丽娅，等.中医辨证论治与红霉素疗法治疗支气管扩张症稳定期的对比研究[J].世界中医药，2015，32（10）：1532-1535.
|
| [10] |
原芳，李向辉，张爱枝，等.小剂量红霉素长期口服对支气管扩张症患者感染稳定期链球菌耐药性和氧化应激蛋白的影响[J].东南国防医药，2016，18（5）：511-514.
|
| [11] |
杨波.沙美特罗替卡松与小剂量红霉素联合治疗支气管扩张症36 例疗效分析[J].中外女性健康研究，2015，25（8）：98.
|
| [12] |
赵丽.小剂量红霉素长期口服治疗稳定期支气管扩张症的临床效果[J].中国现代药物应用，2019，13（22）：151-152.
|
| [13] |
陈晶晶.沙美特罗氟替卡松联合小剂量红霉素治疗支气管扩张症的临床疗效评价[J].当代医学，2018，24（18）：82-84.
|
| [14] |
董燕.长期吸入沙美特罗联合小剂量红霉素口服治疗支气管扩张症80 例[J].世界临床医学，2016，10（1）：73，78.
|
| [15] |
戴泳君，王惠娟，董中国，等.沙美特罗氟替卡松联合小剂量红霉素治疗支气管扩张症的疗效评价[J].黑龙江医药科学，2018，41（6）：20-21.
|
|
|
|
